Dr. Penson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
55 Fruit St Yaw 9
Hematology/Oncology
Boston, MA 02114Phone+1 617-724-5951Fax+1 617-724-6898- Is this information wrong?
Summary
- Dr. Richard Penson is a medical oncologist in Boston, MA at the Massachusetts General Hospital. He received his medical degree from Bart's and has been in practice 30 years. He is a key opinion leader in gynecologic cancer.
Education & Training
Barts and The London SOM & DentClass of 1987, MBBS, MRCP MD
Certifications & Licensure
MA State Medical License 2004 - 2025
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Carboplatin Taxol Avastin in Ovarian Cancer (OVCA) Start of enrollment: 2005 Jun 01
- GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer Start of enrollment: 2004 Dec 01
- Neuropathic Pain in Patients With Cancer Start of enrollment: 2006 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsOlaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.Drew, Y., Kim, J., Penson, R., O'Malley, D., Parkinson, C., Roxburgh, P., Plummer, R., Im, S., Imbimbo, M., Ferguson, M., Rosengarten, O., Steeghs, N., Kim, M., Gal-Ya...> ;Clinical Cancer Research. 2024 Jan 5
- 1 citationsPhase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer.Richard T Penson, Allison J Ambrosio, Christin A Whalen, Carolyn N Krasner, Panagiotis A Konstantinopoulos, Charles Bradley, Ursula A Matulonis, Michael J Birrer> ;The Oncologist. 2023 Mar 17
- 16 citationsA Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer.Kolin, D., Kolin, D., Panagiotis A Konstantinopoulos, Elizabeth K Lee, Niya Xiong, Carolyn Krasner, Susana Campos, David L Kolin, Joyce F Liu, Neil Horowitz, Alexi A W...> ;Journal of Clinical Oncology. 2023 Jan 20
- Join now to see all
Lectures
- Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 tr...2019 ASCO Annual Meeting - 6/1/2019
- Clinical trial in progress: A study of VB-111 combined with paclitaxel vs. paclitaxel for treatment of recurrent platinum-resistant ovarian cancer (OVAL, VB-111-701/GO...2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Other
- Cisplatin nephrotoxicityPenson RT, Safar AM, Portilla D, Shannon ML
http://www.uptodate.com/contents/cisplatin-nephrotoxicity
UpToDate, Wolters Kluwer Health - 2012-08-13 - Clinical features, diagnosis, staging, and treatment of uterine carcinosarcomaPenson RT, Powell MA
http://www.uptodate.com/contents/clinical-features-diagnosis-staging-and-treatment-of-uterine-carcin
UpToDate, Wolters Kluwer Health - 2013-04-01
Press Mentions
What’s Next for Immunotherapy in Ovarian Cancer After “Disappointing” VB-111 Results?August 8th, 2022- Olaparib Did Not Improve PFS2, OS in SOLO3 TrialMarch 19th, 2022
The 6th Biennial Meeting of the Asian Society of Gynecologic Oncology, October 10th to 12th, 2019July 3rd, 2020- Join now to see all
Professional Memberships
- Member
Other Languages
- French
Hospital Affiliations
Massachusetts General HospitalBoston, Massachusetts
Nantucket Cottage HospitalNantucket, Massachusetts
Martha's Vineyard HospitalOak Bluffs, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
